- Roche to invest USD 50 billion in the United States over five years.
- Investment to create over 12,000 new jobs, including 1,000 at Roche.
- New sites in Pennsylvania, Indiana, and Massachusetts will boost production.
Roche (RHHBY, Financial) has announced a substantial investment of USD 50 billion in the United States over the next five years. This strategic move aims to bolster the company's manufacturing and distribution capabilities, focusing on innovative pharmaceuticals and diagnostics.
The investment will lead to the establishment of new research and development sites, along with expanded manufacturing facilities in Indiana, Pennsylvania, Massachusetts, and California. A further site is yet to be announced. These initiatives are expected to create more than 12,000 jobs, including 1,000 positions at Roche and 6,500 construction jobs.
Key projects under this initiative include a state-of-the-art gene therapy manufacturing facility in Pennsylvania, a 900,000 square foot center for weight loss medicines, a continuous glucose monitoring facility in Indiana, and a new AI-focused R&D center in Massachusetts dedicated to cardiovascular research.
With an existing workforce of over 25,000 employees across 24 sites in eight US states, Roche's expansion aims to transform its status to a net exporter of medicines from the US. The company's diagnostics division already maintains an export surplus from the US to other global markets.
This monumental investment underscores Roche's commitment to innovation and growth in the US market, aligning with its long-standing heritage in research and development since its founding in 1896.
